干扰素α-2b联合α1胸腺肽治疗慢性乙型肝炎疗效分析

Curative effect analysis of interferon alpha-2b combined with thymosin alpha 1 in treatment of chronic hepatitis B

目的探究干扰素α-2b联合α1胸腺肽治疗慢性乙型肝炎的临床疗效。方法将160例慢性乙型肝炎患者随机分为两组,即对照组经干扰素α-2b治疗,观察组在此基础上经α1胸腺肽治疗。再比较两组疗效。结果观察组治疗6个月ALT、AST复常率分别为45.0%、50.0%,对照组分别为18.8%、17.5%,差异有统计学意义(P<0.05);观察组治疗6、9、12个月HBs Ag转阴率分别为21.3%、3.2%、32.5%,对照组分别为5.0%、12.5%、15.0%,差异有统计学意义(P<0.05);观察组治疗6、9、12个月HBV DNA转阴率分别为58.8%、62.5%、62.5%,对照组分别为31.3%、36.3%、36.3%,差异有统计学意义(P<0.05);两组治疗6、12个月QOL各领域评分均显著优于治疗前(P<0.05);观察组治疗6个月生理、社会关系评分分别为(63.1±10.2)分、(60.4±12.7)分显著高于对照组,差异具有统计学意义(P<0.05);观察组治疗12个月生理、心理及社会关系评分分别为(65.4±11.1)分、(64.6±13.5)分、(62.4±12.6)分显著高于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论慢性乙型肝炎患者经干扰素α-2b联合α1胸腺肽治疗,可有效清除HBV,提高患者免疫力,控制发生不良反应,疗效确切,值得临床推广应用。

Objective To explore clinical curative effect of interferon alpha-2b combined with thymosin alpha 1 in treatment of chronic hepatitis B. Methods 160 patients with chronic hepatitis B were randomly allocated to the control group and the observation group. The control group was treated by interferon alpha-2b while the observation group was received thymosin alpha 1 at the basis of the treatment in the control group. Curative effects of two groups were compared. Results AST and ALT normalization rate of 6 months after treatment of the observation group were 45% and 50% respectively and those of the control group respectively were 18.8% and 17.5% respectively（P〈0.05）. Negative rates of HBs Ag of 6, 9 and 12 months after treatment of the observation group were 21.3%, 3.2% and 32.5% respectively while those of the control group were 5.0 %, 12.5 % and 15.0% respectively（P〈0.05）. In addition, negative rates of HBV DNA of 6, 9 and 12 months after treatment of the observation group were 58.8%, 62.5% and 62.5% respectively while those of the control group were 31.3%, 36.3% and 36.3% respectively（P〈0.05）. QOL scores of 6 and 12 months after treatment of two groups were both significantly better than those before treatment（P〈0.05）. The scores of physiological and social relations of the observation group were（63.1±10.2） score and（60.4±12.7） score respectively, significantly higher than those of the control group, and the differences had statistical significance（P〈0.05）. The scores of physical, psychological and social relationship of the observation group were（65.4±11.1）score,（64.6±13.5）score and（62.4±12.6）score respectively, significantly higher than those of the control group（P〈0.05）. There was no statistical significance when incidences of adverse reactions in two groups were compared（P〈0.05）. Conclusion Interferon alpha-2b combined with thymosin alpha 1 in treatment of patients with chronic hepatitis B can effectively remove HBV, improve patients＇ immunity and control the occurrence of adverse reactions. It has an accurate curative effect, worthy of clinical promotion and application.